J. Goldman & Co’s Viking Therapeutics VKTX Stock Holding History

J. Goldman & Co’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$526K	–	755
2025 Q3	$526K	Buy	+20,000	New	+$597K	0.01%	375
2025 Q2	–	Sell	-33,600	Closed	-$811K	–	649
2025 Q1	$811K	Buy	33,600 +13,600	+68%	+$430K	0.02%	375
2024 Q4	$805K	Hold	20,000	–	–	0.02%	343
2024 Q3	$1.27M	Sell	20,000 -13,500	-40%	-$792K	0.04%	266
2024 Q2	$1.78M	Buy	+33,500	New	+$2.2M	0.05%	256
2023 Q1	–	Sell	-103,800	Closed	-$976K	–	489
2022 Q4	$976K	Buy	+103,800	New	+$463K	0.05%	226

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

J. Goldman & Co's VKTX Position: Q1 2026 in Review

J. Goldman & Co reduced its Viking Therapeutics (VKTX) stake by 55% in Q1 2026, selling an estimated $590K and leaving 15,294 shares worth $498K. The position accounts for 0.01% of the portfolio, ranked #505.

J. Goldman & Co first reported a position in VKTX in Q2 2018 and has held it in 7 quarters since. The position peaked at $1.18M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

J. Goldman & Co held 15,294 shares of Viking Therapeutics worth $498K as of Q1 2026.
J. Goldman & Co sold 18,364 Viking Therapeutics shares in Q1 2026, an estimated $590K.
Viking Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #505 holding.
J. Goldman & Co first reported a position in Viking Therapeutics in Q2 2018 and has held it in 7 quarters since.
J. Goldman & Co's Viking Therapeutics position peaked at $1.18M in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.